Clinical Trial Update: A Study of Fitusiran in Severe Hemophilia A and B Patients Previously Receiving Factor or Bypassing Agent Prophylaxis [Phase 3]

View source ↗

Summary

Phase 3 trial evaluating fitusiran in severe hemophilia A and B patients previously on factor or bypassing agent prophylaxis has completed with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hemophilia

Drugs mentioned

• Fitusiran (fitusiran)

Snippet

Sponsor: Genzyme, a Sanofi Company | Conditions: Hemophilia | Phase 3 | Status: COMPLETED | Results posted: 2023-02-06